SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Keeta is a high-performance layer-1 blockchain designed to unify transactions across different blockchains and fiat payment systems, eliminating the need for costly intermediaries, reducing fees, and enabling near-instant settlements. With 400-millisecond transaction finality and the ability to process 10 million transactions per second, Keeta sets a new industry benchmark for speed and scalability.  Founded in 2022 and backed by Eric Schmidt, the former CEO of Google, Keeta has been engineered to meet the stringent regulatory and operational requirements of financial institutions. Its advanced on-chain compliance protocols, including KYC and AML, ensure security and regulatory adherence. Keeta’s architecture natively supports asset tokenization and digital identity, making it an ideal platform for stablecoins and real-world asset transfers.  By facilitating cross-chain transactions and interoperability with existing payment systems, Keeta bridges the gap between cryptocurrencies and fiat, enabling a secure, efficient, and compliant global financial ecosystem.

Keeta

Keeta (KTA) is drawing significant attention for its high-performance, compliance-first infrastructure, recently boosted by a strategic integration offering seamless fiat on-ramps. The community is actively discussing its potential as an undervalued foundational layer, poised to become essential global financial plumbing for regulated settlement and cross-chain interoperability.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is a major talking point as the community fervently debates the potential for a significant price surge, fueled by speculation around high short interest and perceived market manipulation. Investors are closely scrutinizing factors like store adjustments and the company's substantial cash reserves, while many anticipate a transformative catalyst such as a share buyback or the return of key influential figures. Divergent opinions persist, with some emphasizing deep value and others expressing impatience over the stock's trajectory.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is experiencing significant upward momentum, driven by strong institutional buying and analyst upgrades, with many predicting it is in an "AI memory supercycle" fueled by demand for High-Bandwidth Memory. While bulls celebrate new all-time highs and a seemingly undervalued forward PE, skeptics anticipate a significant pullback due to the stock's rapid rise and historical cyclicality of the memory sector.

Chevron Corp. engages in the provision of oil and gas energy solutions. It provides crude oil and natural gas, manufactures transportation fuels, lubricants, petrochemicals, and additives, and develops technologies that enhance business and the industry. It operates through the Upstream and Downstream segments. The Upstream segment consists of the exploration, development, and production of crude oil and natural gas, the liquefaction, transportation, and regasification associated with liquefied natural gas, the transporting of crude oil by major international oil export pipelines, the processing, transporting, storage, and marketing of natural gas, and a gas-to-liquids plant. The Downstream segment consists of the refining of crude oil into petroleum products, the marketing of crude oil and refined products, the transporting of crude oil and refined products by pipeline, marine vessel, motor equipment, and rail car, and the manufacturing and marketing of commodity petrochemicals and plastics for industrial uses and fuel & lubricant additives. The company was founded on September 10, 1879 and is headquartered in Houston, TX.

Chevron Corp.

Chevron is trending due to the recent capture of Venezuelan President Maduro and President Trump's statements regarding US oil company involvement in Venezuela's vast oil reserves. The community is highly optimistic about CVX, given its unique position as the only major US oil company currently operating there under a special license, anticipating significant upside potential as geopolitical developments unfold, though some discussions highlight concerns about potential oversupply and infrastructure hurdles.

CleanSpark, Inc. is a bitcoin mining technology company, which engages in the management of data centers. Its operations include College Park, Norcross, Washington, Sandersville, Dalton, and Massena. The company was founded by S. Matthew Schultz and Bryan Huber on October 15, 1987 and is headquartered in Henderson, NV.

Cleanspark Inc

CleanSpark is gaining significant attention fueled by a strong Bitcoin rally and heightened anticipation for a major AI/High-Performance Computing deal announcement. Community discussions heavily feature the stock's substantial short interest, leading to widespread speculation about an impending short squeeze, even as some express skepticism regarding the timing and impact of its AI pivot. This blend of crypto momentum and a potential strategic shift defines current sentiment.

Exxon Mobil Corp. engages in the exploration, development, and distribution of oil, gas, and petroleum products. It operates through the following segments: Upstream, Energy Products, Chemical Products, and Specialty Products. The Upstream segment organizes the exploration of crude oil and natural gas. The Energy Products segment includes fuels, aromatics, and catalyst and licensing. The Chemical Products segment offers petrochemicals. The Specialty Products segment provides finished lubricants, basestocks and waxes, synthetics, and elastomers and resins. The company was founded by John D. Rockefeller in 1882 and is headquartered in Spring, TX.

Exxon Mobil Corp.

Exxon Mobil Corp

Exxon Mobil is currently trending amidst significant geopolitical developments concerning Venezuela's vast oil reserves, fueling widespread speculation about the potential for U.S. oil companies to re-engage with the region. The community is actively discussing expectations of increased profitability and a potential breakout from multi-year price consolidation, while also weighing the implications of potential crude supply changes.

The Stellar network is an open source, distributed, and community owned network used to facilitate cross-asset transfers of value. Stellar aims to help facilitate cross-asset transfer of value at a fraction of a penny while aiming to be an open financial system that gives people of all income levels access to low-cost financial services. Stellar can handle exchanges between fiat-based currencies and between cryptocurrencies. Stellar.org, the organization that supports Stellar, is centralized like XRP and meant to handle cross platform transactions and micro transactions like XRP. However, unlike Ripple, Stellar.org is non-profit and their platform itself is open source and decentralized.   Stellar was founded by Jed McCaleb in 2014. Jed McCaleb is also the founder of Mt. Gox and co-founder of Ripple, launched the network system Stellar with former lawyer Joyce Kim. Stellar is also a payment technology that aims to connect financial institutions and drastically reduce the cost and time required for cross-border transfers. In fact, both payment networks used the same protocol initially.  Distributed Exchange Through the use of its intermediary currency Lumens (XLM), a user can send any currency that they own to anyone else in a different currency.  For instance, if Joe wanted to send USD to Mary using her EUR, an offer is submitted to the distributed exchange selling USD for EUR. This submitted offer forms is known as an order book. The network will use the order book to find the best exchange rate for the transaction in-order to minimize the fee paid by a user.  This multi-currency transaction is possible because of "Anchors". Anchors are trusted entities that hold people’s deposits and can issue credit. In essence, Anchors serves as the bridge between different currencies and the Stellar network.  Lumens (XLM) Lumens are the native asset (digital currency) that exist on the Stellar network that helps to facilitate multi-currency transactions and prevent spams. For multi-currency transactions, XLM is the digital intermediary that allows for such a transaction to occur at a low cost.  In-order to prevent DoS attacks (aka spams) that would inevitably occur on the Stellar network, a small fee of 0.00001 XLM is associated with every transaction that occurs on the network. This fee is small enough so it does not significantly affect the cost of transaction, but large enough so it dissuades bad actors from spamming the network.   Prior to Protocol 12, Stellar had a built-in inflation mechanism conceived to allow account holders to collectively direct inflation-generated lumens toward projects built on Stellar.  As the network evolved and grew, it became increasingly clear that inflation wasn’t working as intended — account holders either didn’t set their inflation destination or joined inflation pools to claim the inflation themselves, and the operational costs associated with inflation payments continued to rise — and so a protocol change to disable inflation was proposed, implemented, voted on by validators, and ultimately adopted as part of a network upgrade.  The inflation operation is now deprecated. https://developers.stellar.org/docs/glossary/inflation/

Stellar Lumens

Stellar Lumens is trending due to significant institutional developments, including U.S. Bank testing stablecoin issuance, PayPal's PYUSD natively integrating, inclusion in a Franklin Templeton ETF, and its involvement in the new Blockchain Payments Consortium. The community is actively debating XLM's position in the evolving financial infrastructure, with many highlighting its ISO 20022 compliance and network upgrades aimed at institutional adoption, while a counter-narrative questions its long-term growth trajectory.

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is generating significant buzz following its record-breaking delivery numbers and strong quarterly performance, positioning the company closer to profitability and a major cumulative production milestone. Despite this operational strength, community discussion is dominated by frustration over perceived stock price manipulation and a valuation disconnect, particularly when considering its innovative battery swapping network and global expansion.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Denver, CO.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir Technologies is trending amidst widespread speculation that its advanced AI and data analytics platforms were instrumental in a recent high-profile US military operation in Venezuela. This has ignited strong bullish sentiment, with discussions centering on potential new government contracts and its critical national security capabilities. However, a significant portion of the community remains cautious, emphasizing the stock's high valuation and debating the long-term impact of such an event on its fundamental trajectory.

Onyx is an infrastructure for a multi-asset, scalable, and cryptographically secure ledger. Onyx functions as a blockchain-based technology that enhances financial ecosystems by enabling a more efficient and interconnected economy, with a mission to develop cryptographic ledgers that optimize security, scalability, and usability. XCN is native to the Onyx XCN Ledger Blockchain and as an ERC-20 token for Staking and Governance.

Onyxcoin

Onyxcoin is trending following its listing on Robinhood and the delisting of its futures contracts from a major exchange, which proponents view as key steps towards greater legitimacy and reduced manipulative short pressure. The community is sharply divided; while many anticipate future institutional adoption driven by the upcoming Goliath Mainnet and Chain's ISO 20022 integration, skeptics highlight past price volatility and question the project's long-term viability amidst broader market sentiment.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Azitra stated that its data showed positive outcomes as the company advances towards a first-in-human clinical trial of the skin disorder.</li><li>The company noted that ichthyosis vulgaris impacts 1.3 million people in the U.S., who have no treatment options apart from managing the symptoms.</li><li>Some of the symptoms of ichthyosis vulgaris include severe dry skin and scales, which can appear on the face, back of the arms, legs, back, or stomach.</li></ul>Azitra Inc. (AZTR) on Monday announced positive preclinical data for its ATR-01 program, which is designed to treat ichthyosis vulgaris, a skin disorder that most often appears in early childhood.<h2 class="st-heading-2">Ichthyosis Vulgaris Affects 1.3 Million People In The U.S.</h2>Azitra stated that its data showed positive outcomes as the company advances towards a first-in-human clinical trial of the skin disorder. The company noted that ichthyosis vulgaris impacts 1.3 million people in the U.S., who have no treatment options apart from managing the symptoms.<blockquote>“We are optimistic that this innovative, topically delivered treatment option has the potential to directly address the disease pathophysiology. We look forward to further updates on this program in 2026, including details around a path to first-in-human studies."– Francisco Salva, CEO, Azitra</blockquote><a href="https://stocktwits.com/symbol/AZTR">Azitra shares</a> soared more than 56% in Monday’s pre-market trade. Retail sentiment on Stocktwits around the company trended in the ‘bullish’ territory at the time of writing.<h2 class="st-heading-2">What Is Ichthyosis Vulgaris?</h2>Ichthyosis vulgaris is a common skin disorder that causes dry, scaly skin. Some of the symptoms include severe dry skin and scales, which can appear on the face, back of the arms, legs, back, or the stomach,&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://my.clevelandclinic.org/health/diseases/21069-ichthyosis-vulgaris">according</a> to the Cleveland Clinic. Some of the options available to manage these symptoms include frequent moisturization using topical exfoliants or oral retinoids in severe cases.Get updates to this story developing <a href="https://stocktwits.com/news-articles/markets/equity/azitra-shares-soar-premarket-positive-preclinical-data-ichthyosis-vulgaris/ch6CHUIR3Ym">directly on Stocktwits</a>.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/dow-futures-edge-up-major-earnings-week/ch6CM53R3Yh">Dow Futures Edge Up As Investors Turn Attention To Major Earnings Week: AMZN, BA, NVDA, ZION Among Stocks To Watch</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Azitra Inc, a micro-cap dermatology company, was among the top trending stocks on Stocktwits on Wednesday.

Azitra Shares Soar Pre-Market: What’s Driving The Surge?

Azitra stated that its data showed positive outcomes as the company advances towards a first-in-human clinical trial of the skin disorder.

Equity

Azitra had its best trading day in more than seven months on Wednesday after disclosing that the first patient had been dosed in its Phase 1/2 trial of ATR04-484, a topical live biotherapeutic being developed to treat rashes caused by EGFR inhibitor (EGFRi) cancer therapies.The stock closed Wednesday up 35.9% at $1.03, before slipping 2.4% in after-hours trading.ATR04-484, which has a fast-track designation from the FDA, is designed to address EGFRi-associated rash, a side effect that affects an estimated 150,000 people in the U.S. each year.&nbsp;These rashes are one of the most common and disruptive side effects of EGFRi cancer drugs, occurring in up to 80% of patients and often severe enough to interrupt treatment.“Dosing the first patient is an important milestone in the advancement of ATR04-484 as a potential treatment for EGFRi-associated rash,” said CEO Francisco Salva. He noted the therapy could help reduce the dermatologic toxicities that limit&nbsp;the use of targeted cancer therapies such as those for lung and colorectal cancers.The randomized, double-blind, vehicle-controlled Phase 1/2 study will evaluate ATR04-484’s safety, tolerability, and efficacy in adult patients, measuring endpoints such as rash severity, itch, and pain.&nbsp;The drug is based on an engineered strain of Staphylococcus epidermidis, designed to reduce IL-36γ and S. aureus levels, both of which are elevated in EGFRi-related rashes.Beyond ATR04-484, Azitra is also advancing ATR-12 for Netherton syndrome, a rare and life-threatening genetic skin disease with no approved therapies. Both programs stem from the company’s dermatology platform, which leverages a microbial strain library and artificial intelligence to identify new drug candidates.On Stocktwits, retail sentiment was ‘extremely bullish’ amid a 4,657% surge in 24-hour message volume.One user said that Azitra shares had been “holding pretty strong,” while others pointed to the surge in trading activity.&nbsp;<stembedurl>https://stocktwits.com/TheStocksDoc/message/626774494</stembedurl><stembedurl>https://stocktwits.com/Thunderman/message/626784109</stembedurl>Wednesday’s turnover reached 110.7 million shares, more than 800 times the stock’s average daily volume of about 132,000.<a href="https://stocktwits.com/symbol/AZTR">Azitra’s stock</a> has declined 63.7% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Azitra’s stock (AZTR) has declined 63.7% so far in 2025. (Photo credit: Getty Images)

Azitra Stock Scores Best Day In 7 Months After First Patient Dosed In Cancer-Linked Skin Rash Trial

The FDA has granted the program Fast Track status, aiming to address rashes that affect roughly 150,000 U.S. patients each year.

U.S. biotech stocks, particularly small and mid-cap companies, remained a focal point for retail investors in 2024 despite significant volatility.&nbsp;Collectively, biotech stocks on U.S. bourses have garnered over 3.3 million watchers on Stocktwits.&nbsp;Here are the top five biotech stocks that saw the most significant surge in new followers this year:CERo Therapeutics Holdings Inc. (CERO): +44544% WatchersThis immunotherapy company develops engineered T-cell therapeutics for cancer. <a href="https://stocktwits.com/symbol/CERO">CERO</a> saw major retail interest following the FDA’s clearance of its lead compound, CER-1236, for Phase 1 clinical trials after an earlier clinical hold. The company went public via a SPAC merger in February and has lost 99% of its value this year.Psyence Biomedical Ltd. (PBM): +6741% WatchersKnown for developing natural psilocybin products for treating psychological trauma, PBM gained attention for positive results from its Phase IIb trial in adjustment disorder treatment for terminal cancer patients.&nbsp;Its&nbsp;shares have also dropped 99% this year since the company’s March SPAC debut.Azitra Inc. (AZTR): +2365% WatchersSpecializing in dermatological therapies using engineered proteins and live biotherapeutic products, AZTR drew attention for securing&nbsp;a fast track designation for ATR-04 and other multiple&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-are-azitra-shares-trending-on-wednesday/c7r4UW0RbE">patents</a>. Its stock value has plunged more than 99% since its debut in June last year.Immuneering Corporation (IMRX): +2248% WatchersFocused on oncology, IMRX’s lead program, IMM-1-104, received FDA orphan drug designation for pancreatic cancer and fast-track status to treat certain melanoma patients, and is currently in a Phase 2a trial. <a href="https://stocktwits.com/symbol/IMRX">IMRX shares</a> have declined over 70% year-to-date.NKGen Biotech Inc. (NKGN): +1260% WatchersNKGN develops autologous and CAR-NK cell therapies. Its SNK01 natural killer cell therapy for Alzheimer’s disease showed promising results, with 90% of patients maintaining or improving cognitive function. The candidate was cleared to progress into phase 2 clinical development, which will involve a larger group of 30 patients with moderate Alzheimer's disease. Shares, however, have fallen more than 66% this year.Despite their stock price struggles, these companies have captivated retail investors with groundbreaking therapies and promising clinical developments, positioning them as key biotech names to watch heading into 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Woman examining laboratory samples - stock photo | Image source: Getty Images

Top 5 Biotech Stocks That Captured Retail Investor Interest The Most In 2024

Despite their stock price struggles, these companies have captivated retail investors with groundbreaking therapies and promising clinical developments.

Azitra Inc, a micro-cap dermatology company, was among the top trending stocks on Stocktwits on Wednesday morning after it announced two developments on Tuesday. The firm said the US Patent and Trademark Office (USPTO) has granted a patent that covers future potential pipeline candidates for indications including atopic dermatitis.Apart from this, the company also announced three additional newly allowed patents in three countries, including the US, Canada, and China. Following the announcement, the stock had closed over 200% higher on Tuesday. However, a large portion of the gains were pared in Wednesday’s pre-market session with the stock losing over 75% ahead of the market open.Following the development, the stock gained a lot of traction on Stocktwits. Tuesday’s page views for the symbol on Stocktwits stood at 220x their daily average of the previous month. Total user messages on the Azitra symbol page grew from a handful per day to over 1,000 on Tuesday while total number of users with the stock symbol on their watchlist grew by nearly 1,000 to roughly 1,600 as of Wednesday morning.The firm expressed optimism about its new patents. Azitra’s COO and co-founder Travis Whitfill pointed out that atopic dermatitis affects approximately 16.50 million people in the United States. “There are numerous diseases associated with filaggrin deficiency, and the newly issued U.S. patent extends our protection to include a major market in the U.S., atopic dermatitis, particularly those with mild to moderate disease. Additionally, the new patent allowances in China and Canada extend our IP strength globally,” he said.Meanwhile, the firm also announced a $10 million fundraise via common shares and warrants priced at $1.50. The company said it intends to use the net proceeds from this offering for working capital and general corporate purposes, but the dilution is weighing heavily on shares Wednesday morning.Stocktwits users are chatting about the stock’s sudden dip after Tuesday’s optimism. One user named “dt2011” pointed out the benefits of taking profits when opportunity allows.<figure class="image"><a href="https://stocktwits.com/dt2011/message/580521550"><img style="aspect-ratio:815/263;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_07_24_at_9_18_29_AM_8c732d9994.png" alt="Stocktwits user dt2011's post on Azitra Inc" width="815" height="263"></a><figcaption>Stocktwits user dt2011's post on Azitra Inc</figcaption></figure>

Azitra Stock Witnesses 220x Page Views On Stocktwits After These Developments 

The stock closed over 200% higher on Tuesday after the firm reported multiple patent wins. Still, investors are not very enthused with the company’s latest public offering worth $10 million

Azitra, Inc. is an early-stage clinical biopharmaceutical company, which engages in the development of therapeutic use in dermatology. The firm is involved in using engineered proteins and live bio therapeutic products that can be applied topically to treat diseases of the skin. It also offers a platform which is augmented by artificial intelligence and machine learning technology that analyzes, predicts, and helps screen library of strains for drug like molecules. The company was founded by Azim Munivar and Travis Whitfill on January 2, 2014 and is headquartered in Branford, CT.

AZTR
Azitra Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest AZTR News

AZTRAzitra Inc